articleThe Lancet OncologyJul 19, 2017GREEN OA

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

The University of Texas MD Anderson Cancer Center · St. Vincent's University Hospital · +13 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

2,800
total citations
FWCI
106.51
Percentile
100%
References
37
Citations per year

Authors

16

Topics & keywords

Keywords
  • Nivolumab
  • Medicine
  • Irinotecan
  • Microsatellite instability
  • Colorectal cancer
  • Internal medicine
  • Oncology
  • Clinical endpoint
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.